Global Wellness Strategies Forms Pharma Subsidiary Focused on Clinical Trials
Global Wellness Strategies Forms Pharma Subsidiary Focused on Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X) (OTCQB: GWSFF) ("Global" or the "Company") a prospect generator that provides high growth companies with financial, operational, and management assistance focused in health and wellness announces the formation of a wholly owned pharma subsidiary focused on clinical trials.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年11月17日)-全球健康戰略公司(CSE：GWS)(FSE：O3X)(OTCQB：GWSFF)(“全球”或“公司”)一家為高增長公司提供專注於健康和健康的財務、運營和管理援助的前景生成器宣佈成立一家專注於臨牀試驗的全資製藥子公司。
"Real strategic capital market partnerships are essential to assist our clients in their progression to the next level with their organic growth. Forming a pharma subsidiary focused primarily on funding clinical trials is essential to our partners' successes," stated Meris Kott, CEO, Global Wellness Strategies Inc.
Global Wellness Strategy Inc.首席執行官梅里斯·科特表示：“真正的戰略資本市場夥伴關係對於幫助我們的客户發展到下一個水平，實現他們的有機增長至關重要。成立一家主要為臨牀試驗提供資金的製藥子公司對我們合作伙伴的成功至關重要。”
Global Wellness acquired Shanti Therapeutics in 2022 and all share issuances for the acquisition have been completed. iNGENü a subsidiary of Australian leader Cannvalate is engaged as the CRO (clinical research organization) by the Company to conduct clinical trials for Shanti Therapeutics. The protocol is a single center, randomized crossover study to investigate the efficacy of MDMA vs placebo in a model of experimental pain in healthy adults. Shanti has a targeted research pathway to clinical success, with strong proprietary protection under its already submitted patent providing a method for the treatment or prevention of pain. Canada-based PharmAla Biotech is to supply MDMA for the Shanti Therapeutics upcoming clinical trial and will disclose receipt of MDMA shortly as the Company readies for its import permit to Australia.
Global Wellness於2022年收購了Shanti Treeutics，此次收購的所有股票發行已經完成。Ingenü是澳大利亞領導者Cannvalate的子公司，被該公司聘請為臨牀研究機構，為Shanti治療進行臨牀試驗。該方案是一項單中心、隨機交叉研究，旨在研究MDMA與安慰劑在健康成年人實驗性疼痛模型中的療效。Shanti有一條通往臨牀成功的有針對性的研究途徑，其已經提交的專利提供了治療或預防疼痛的方法，具有強大的專利保護。總部位於加拿大的PharmAla Biotech將為Shanti治療公司即將進行的臨牀試驗提供MDMA，並將很快披露MDMA的接收情況，因為該公司準備向澳大利亞進口許可證。
Global Wellness brands broadened their Canadian footprint with provincial partnerships and received a notice of acceptance recently for three new SKUs from the Ontario Cannabis Store (OCS) for GWS and Sunshine State Tea products. The SKU bundles will be available in adult dispensaries in early 2023 in Ontario. The Company will file patents for their formulations and are researching a Contract Research Organization (CRO) in the UK to begin cannabis trials on these products.
Global Wellness品牌通過省級合作伙伴關係擴大了在加拿大的足跡，最近收到了接受安大略省大麻商店(OCS)為GWS和陽光州茶葉產品提供的三個新SKU的通知。SKU捆綁包將於2023年初在安大略省的成人藥房提供。該公司將為他們的配方申請專利，並正在研究英國的一個合同研究組織(CRO)，以開始對這些產品進行大麻試驗。
Corporate Update:
企業動態：
The Company has appointed Meris Kott as CEO of Shanti Therapeutics as the team readies for the first human clinical trials in Melbourne, Australia.
該公司已任命Meris Kott為Shanti治療公司的首席執行官，該團隊正準備在澳大利亞墨爾本進行第一次人體臨牀試驗。
The Medical Advisory board at Global Wellness welcomes the team of BioMed360 Solutions Corp to the company in conjunction with the formation of the pharma subsidiary. Since 2019, BM360 has been focused on identifying cutting edge biotech and medical technology platform solutions within the medical and pharmaceutical industries. Most recently, BioMed360 is engaging with clinical stage biotechnology companies entering human clinical trials for various diseases including diabetes and forms of cancer.
Global Wellness的醫療顧問委員會歡迎BioMed360 Solutions Corp的團隊與製藥子公司的成立一起加入公司。自2019年以來，BM360一直專注於識別醫療和製藥行業內的尖端生物技術和醫療技術平臺解決方案。最近，BioMed360正在與臨牀階段的生物技術公司合作，進入各種疾病的人體臨牀試驗，包括糖尿病和各種形式的癌症。
About Global Wellness Strategies:
關於全球健康戰略：
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.
Global Wellness Strategy是一個前景創造者，在快速增長的健康消費品市場為高增長的公司提供財務、運營和管理方面的幫助。該公司專注於全球健康、迷幻藥、真菌學、大麻和CBD，以及與醫療保健相關的目標公司。
For further information visit websites:
欲瞭解更多信息，請訪問以下網站：
Or Contact Meris Kott CEO 604.484.0355 or email to info@globalwellnessstrategies.com
或聯繫Meris Kott首席執行官604.484.0355，或發送電子郵件至info@global alwell nessstrategies.com
Further information about the Company is available on under the Company's profile.
欲瞭解更多有關本公司的信息，請訪問：本公司簡介。
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。本新聞稿中包含的某些陳述可能構成“前瞻性陳述”或“前瞻性信息”(統稱為“前瞻性信息”)，因為這些術語在1995年的“私人證券訴訟改革法”和類似的加拿大法律中使用。這些陳述與未來的事件或未來的表現有關。使用“可能”、“打算”、“預期”、“相信”、“將”、“預計”、“估計”、“預期”以及與非歷史事實有關的類似表述和陳述，旨在識別前瞻性信息，並基於公司對此類未來事件的結果和時機的當前信念或假設。未來的實際結果可能會有很大不同。特別是，本新聞稿包含與該公司的業務、其融資和某些公司變化有關的前瞻性信息。本新聞稿中包含的前瞻性信息是截至本新聞稿發佈之日的信息，公司沒有義務因新信息、未來事件或其他原因而更新或修改任何前瞻性信息，除非適用的證券法要求這樣做。由於本文包含的風險、不確定性和假設，投資者不應過度依賴前瞻性信息。上述陳述明確表示，本文中包含的任何前瞻性信息都是合格的。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。